Experiment 1 was conducted to examine the optimum duration of N-butyl-N-(4-hydroxybutyl) 43 •`49, 1996) 
Introduction
Human bladder carcinoma can be mainly divided into two types: papillary non-invasive type and non-papillary invasive type. The former is often treated using transurethral resection (TUR), however this type has a high recurrence rate during follow-up. On the other hand, the latter is often fatal. These two different types of carcinoma of the urinary bladder have different patterns of growth and progression. Establishment of animal models of bladder carcinoma is essential in analyzing factors related to the onset and progression of bladder car cinoma and in obtaining basic data for useful refer ence when diagnosing and treating this cancer. Experimental models of human bladder carcinoma should have a manner of histogenesis and progression similar to the natural history of human bladder carcinoma.
In our previous experiments using rats with bladder carcinoma induced by N-butyl-N-(4 -hydroxybutyl) nitrosamine (BBN), we examined the effects of treatment with anti-cancer agents on the development of BBN-induced carcinoma, and col lected basic data which would be useful in preventing the recurrence of superficial bladder carcinoma in clinical cases1-4. A similar examination was also carried out using combination chemotherapy5. However, since BBN-induced bladder carcinoma in rats is a model of superficial bladder carcinoma in humans, it was inappropriate to use this rat model for assessing the effects of combination chemotherapy for invasive bladder carcinoma.
In the present study, therefore, we used a mouse model of bladder carcinoma to examine the effects of three combination chemotherapy regimens; 1) CAP regimen containing cyclophosphamide (CPM), pirar ubicin (THP-ADM), and cisplatin (CDDP), 2) M VAC regimen containing methotrexate (MTX), vinb lastine sulfate (VLB), THP-ADM, and CDDP, and 3) MEC regimen containing MTX, epirubicin hydro chloride (Epi-ADM) and CDDP. All animals were divided into six groups ( Fig.  1 ). Group 1 was composed of 50 mice, which were subdivided at random into 7 groups after 4-week BBN treatment and whose bladders were examined histopathologically every 4 weeks from the beginning of the experiment. Group 2 was composed of 50 mice, which were subdivided at random into 6 groups after 8-week BBN treatment and whose bladders were examined at intervals of 4 weeks. Group 3 com prised of 35 mice which were subdivided at random into 5 groups after 12-week BBN treatment and whose bladders were examined at intervals of 4 weeks. Group 4 was composed of 30 mice, which were sub divided at random into 4 groups after 16-week BBN treatment and whose bladders were examined at inter vals of 4 weeks. Group 5 comprised 35 mice, which were subdivided at random into 3 groups after 20
week BBN treatment and whose bladders were obser ved at intervals of 4 weeks.
In Groups 1 through 5, no treatment was undertaken during the observation period.
Group 6 was composed of 35 untreated control mice, which were divided at random into 7 groups and examined at intervals of 4 weeks until the 28th week. All animals from each group were sacrificed by an overdose of ether, and the bladders were inflated in situ with 10% phosphate-buffered formalin solution.
After an overnight fixation, each bladder was cut vertically into 8 to 12 sections, embedded in paraffin, and stained with hematoxylin eosin.
Experiment 2 (CAP experiment)
One hundred and five female C3H/He mice were divided into five groups (Fig. 2 ). The animals al located to Groups 1 and 2 were given water contain ing 0.05% BBN for 12 weeks. The remaining three groups were untreated controls. The animals allocat ed to Groups 2 and 3 received three cycles of CAP therapy, i.e., intraperitoneal injection of physiological saline, containing CPM (45mg/kg, Shionogi & Co., Ltd., Osaka, Japan), THP-ADM (1.5mg/kg, Meiji Seika Kaisha, Ltd., Tokyo, Japan) and CDDP (2.0 mg/kg, Nippon Kayaku Co., Ltd., Tokyo, Japan), at intervals of 3 weeks from the 15th week on ( Table 1) . In Group 4, drug-free physiological saline was intraperitoneally injected in a similar way. Group 5 received no injection. All mice were sacrificed 24 weeks after the beginning of the experiment and the One hundred and ninety-one 6-week-old female OH/He mice were divided into nine groups (Fig. 3 ). The animals allocated to Groups 1 through 4 were given water containing 0.05% BBN for 12 weeks. The remaining five groups were untreated controls. The animals allocated to Groups 2 and 5 received three cycles of M-VAC therapy, i.e., intraperitoneal injection of physiological saline, containing MTX (10 mg/kg, Lederle Japan Co., Ltd., Tokyo), VLB (0.3 mg/kg, Eli Lilly Japan KK, Tokyo, Japan), THP ADM (1.5mg/kg) and CDDP (2.0mg/kg), at inter vals of 4 weeks from the 12th week (Table 2) . Groups 3 and 6 were the low dose MEC groups; they received three cycles of low-dose MEC therapy, i.e., intraperitoneal injection of physiological saline, containing MTX (10mg/kg), Epi-ADM (4.0mg/kg, Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan), and CDDP (3.0mg/kg), at intervals of 4 weeks, starting immediately after the 12-week BBN treatment. Groups 4 and 7 were high dose MEC groups; they received three cycles of intraperitoneal injection of physiological saline, containing MTX (12mg/kg), Epi-ADM (5.0mg/kg) and CDDP (3.5mg/kg) ( Table 3 ). In Group 8, drug-free physiological saline was intraperitoneally injected in a similar way. Group 9 received no injection. All mice were sacrificed in the 24th week, and the bladders were examined histopathologically. Eleven animals died of weakness for a term of experiment. They were treated with 0.05% BBN for more than 8 week, and observed more than 20 weeks. In all groups 1 through 6, histopathological examina tion of the bladders yielded the following results (Table 4 ).
Dysplasia developed in 10-20% of the animals in Group 1, in which they were treated with 0.05% BBN for 4 weeks and subsequently observed without BBN treatment until the 28th week at intervals of 4 weeks.
In Group 2 where BBN was given for 8 weeks and observation was subsequently made at intervals of 4 weeks until the 28th week, the incidence of dysplasia was 7-60% and that of carcinoma was 11 -40%. Of various types of carcinoma, CIS (carcinoma in situ) had an incidence of 20%, superficial car cinoma had an incidence of 7-20% and invasive carcinoma had an incidence of 7-20%. In Group 3 where BBN was administered for 12 weeks, the incidence of dysplasia was 40-100% and that of carcinoma was 20-100% (14-80% for CIS, 20-60% for superificial carcinoma and 20-57% for inva sive carcinoma). In Group 4 in which BBN was administered for 16 weeks, the incidence of dysplasia was 80-100% and that of carcinoma was 60-100% (38-40% for CIS, 20 -63% for superficial carcinoma and 20-88% for invasive carcinoma). In Group 5 where BBN was administered for 20 weeks, both dysplasia and carcinoma had an inci dence of 100%. Of various types of carcinoma, CIS had an incidence of 23-60%, superficial carcinoma had an incidence of 54-90% and invasive carcinoma had an incidence of 40-100%. All mice from Group 6 (untreated controls) had normal bladders.
Histopathological examination of the bladders yielded the following results ( Table 5 ). In the BBN alone group, the incidence of carcinoma was 18/18 (100%), 2/18 (11%) developed CIS, 10/18 (56%) devel oped superficial carcinoma and 14/18 (78%) devel oped invasive carcinoma. In the BBN+CAP treat ment group, the incidence of carcinoma in general being 20/27 (74%), CIS, superficial carcinoma, and invasive carcinoma developed in 2/27 (7%), 13/27 (48%), and 7/27 (26%), respectively. The incidence of invasive carcinoma differed significantly between these two groups (p<0.025). In the control groups (Groups 3, 4, and 5), no animal developed tumors.
Experiment 3 (M-VAC, MEC experiment)
Histopathological examination of the bladders yielded the following results (Table 6 ). Of the 27 mice treated with BBN alone, the incidence of car cinoma was 21/27 (78%), 4/27 (15%) developed CIS, 9/27 (33%) developed superficial carcinoma, and 18/27 (67%) developed invasive carcinoma. In the BBN+M-VAC treatment group, the incidence of carcinoma in general being 19/27 (70%), CIS, superficial carcinoma, and invasive carcinoma was 1/27 (4%), 3/27 (11%), and 14/27 (52%), respectively. In the BBN+low dose MEC treatment group, the in cidence of carcinoma in general, CIS, superficial carcinoma, and invasive carcinoma were 11/29 (38%), 6/29 (21%), 7/29 (24%), and 4/29 (14%), respectively. In the BBN+high dose MEC treatment group, the respective incidences were 9/28 (32%), 2/28 (7%),4/28 (14%), and 4/28 (14%). The incidence of carcinoma differed significantly between the BBN group and the BBN+low dose MEC, high dose MEC treatment groups (p<0.005) and between the BBN+M-VAC group and the BBN+low dose MEC, high dose MEC treatment groups (p<0.025, p<0.005). The inci dence of superficial carcinoma differed significantly between the BBN group and the BBN+M-VAC, BBN+high dose MEC treatment groups (p<0.05, p<0.1).
The incidence of invasive carcinoma differed significantly between the BBN group and BBN+low dose MEC, high dose MEC treatment groups (p<0.001) and between the BBN+M-VAC group and BBN+low dose MEC, high dose MEC treatment groups (p<0.005). In the control groups (Groups 6 through 9), no mouse developed tumor.
Discussion
To create a valid experimental model of human bladder carcinoma, it is necessary that: (1) the car cinogen has its target only in the urinary bladder; (2) the carcinogen is administered via a natural route;
(3) carcinogenesis can be induced at a high incidence in short periods of time; (4) the carcinoma induced is histopathologically similar to human bladder car cinoma; and (5) the carcinoma induced can be diagnosed and treated using techniques employed for clinical cases. Induction of bladder carcinoma by treating dogs, medium-sized experimental animals, and smaller rats or mice with BBN is often used to create an experimental model of human bladder carcinoma which satisfies these requirements.
The experimental model, which involves treat ment of dogs with BBN, was developed at our laboratory6,7. By adjusting the dose level and dosing period of BBN, it is possible to induce papillary non invasive carcinoma and non-papillary invasive car cinoma, resembling those of humans, in the urinary bladders of dogs. Our detailed histopathological examination of the manner of tumor development and progression in mouse bladders revealed that treatment with BBN first causes thickness of the bladder mucosa (i.e., develop ment of simple hyperplasia), and that this is followed by the development of dysplasia. Bladder dysplasia has been thought to develop into CIS and then into non-papillary invasive carcinoma, although it is also possible that dysplasia sometimes shows papillary growth and advances into papillary invasive car cinoma.
Total cystectomy is often used for surgical treat ment of human invasive bladder carcinoma. How ever, treatment using surgery alone does not yield satisfactory results. For this reason, multi-discipli nary therapy, using a combination of radical surgery and adjuvant therapy, including chemotherapy, im munotherapy, and radiotherapy, has been used. Preoperative adjuvant therapy is primarily intended to: (1) reduce the size or stage of tumors as far as possible so that subsequent surgery can be performed more easily, (2) reduce the viability of tumor cells so that local or systemic spread of tumors can be prevent ed, and (3) treat micrometastasis which may be present10. Postoperative adjuvant therapy should be provided as far as possible, if we consider that surgical manipulations can induce the spread of tumor cells.
In the present study, a mouse model of BBN induced bladder carcinoma was created in Experi ment 1. Using this model, the effects of three regi mens of combination chemotherapy (CAP, M-VAC and MEC regimens) in suppressing the development of bladder carcinoma were examined (Experiments 2 and 3).
As compared to the animals in BBN alone groups, the animals treated with BBN and anti-cancer agents had significantly lower incidences of invasive carcinoma in Experiment 2 and significantly lower incidences of invasive carcinoma or superficial car cinoma in Experiment 3, suggesting that these chemotherapeutic regimens are effective in suppress ing the development of invasive bladder carcinoma.
